The Filing Desk

Arcturus Therapeutics vs Eton Pharmaceuticals

Arcturus Therapeutics ARCT · Eton Pharmaceuticals ETON · Pharmaceuticals

Arcturus Therapeutics reported revenue of $82 million in fiscal 2025, about the same as Eton Pharmaceuticals' $80 million in fiscal 2025. Arcturus Therapeutics' revenue fell 46.1% in its latest year, and Eton Pharmaceuticals' grew 104.9%. Arcturus Therapeutics had an operating margin of -93.0%, against -1.1% at Eton Pharmaceuticals. Free cash flow was −$74 million at Arcturus Therapeutics and $10 million at Eton Pharmaceuticals.

Side by side

Arcturus TherapeuticsEton Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$82M$80M
Revenue growth−46.1%104.9%
Revenue growth a year, last 5 years53.9%—
Gross margin—53.5%
Operating margin−93.0%−1.1%
Net margin−80.2%−5.8%
Free cash flow−$74M$10M
Free cash flow margin−90.8%12.8%
Return on capital—−1.9%
Net debt to EBITDA—1.4x
Dividends and buybacks$0M$0M
Change in diluted share count1.4%3.9%
Last close$7.60$61.36
P/E at the last close——
Insider trades, last 12 months—sold $25.2 million
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arcturus TherapeuticsEton Pharmaceuticals
Operating margin
Percent of revenue
Arcturus TherapeuticsEton Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcturus TherapeuticsEton Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcturus Therapeutics and Eton Pharmaceuticals pages.